RETLIRA 30 30mg / 3ml Pen

Key Features

30mg Reta per pen
Each pen contains 30mg in a 3ml solution.

Pre-filled 3ml pen format
No vial mixing or reconstitution required.

Click-based measuring system
Designed for simple, consistent measurement during research use.

Premium lab sourcing
Sourced from a specialist German laboratory.

Includes disposable needle tips
Packaged as a complete research pen kit.

Product Details

Product name: RETLIRA 30
Compound: Reta
Strength: 30mg
Volume: 3ml
Format: Pre-filled research pen
Pack contents: 1 pre-filled pen with disposable needle tips
Use: Research purposes only

Important Notice

This product is supplied strictly for research purposes only. It is not registered as a medicine, is not approved as a treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or animal consumption. Use only in accordance with applicable research and laboratory guidelines.

Concentration: 10mg per 1ml. Dosage: Start at 1mg (10 clicks) per week for the first 4 weeks. Only move up to 2mg (20 click) if you are tolerating the starting dose well with no major side effects.

 Usage & Timing: Inject once weekly on the same day. Timing doesn't matter much for efficacy, but many prefer evening injections to sleep through any initial nausea.

 Injection Method: Administer via a subcutaneous injection (just under the skin) using an insulin syringe. Injection Sites: The best areas are the stomach (two inches from the belly button), the outer thigh, or the back of the arm. Always rotate your injection sites each week to avoid tissue irritation.

Focusing on a high-protein diet is essential to preserve lean muscle mass during rapid weight loss, aiming for at least 1.2 to 1.5 grams of protein per pound of body weight. Reducing caloric intake through smaller, nutrient-dense meals helps manage the delayed gastric emptying and prevents the intense nausea often triggered by large or greasy portions. Sufficient fiber intake from whole foods is critical to maintain regular digestion and prevent the constipation commonly associated with GLP-1 agonists.

Key supplements to support this protocol include:

• Electrolytes: Essential for maintaining hydration and preventing the dizziness or "keto flu" symptoms often felt during titration.
• Digestive Enzymes & Probiotics: Useful for supporting gut health and reducing bloating or slow-digestion issues.
• B-Complex or B12: Often used to combat the fatigue that can occur as the metabolism adjusts.
• Magnesium: Highly effective for supporting healthy sleep and ensuring regular bowel movements.

How is it different from Tirzepatide? It’s a "triple agonist" targeting GLP-1, GIP, and Glucagon for potentially faster fat loss.

1. What is the best starting dose? Standard research starts at 1mg or 2mg weekly to minimize side effects.
2. Does it cause a higher heart rate? Many users report a slight increase in resting heart rate due to the glucagon component.
3. Is "skin sensitivity" a common side effect? Yes, some users report "allodynia" (sensitive skin) during the early stages.
4. How long does a 30mg vial last? At a 2mg/week dose, one 30mg vial lasts 15 weeks.
5. Does it work for "stalled" weight loss? Many switch to Reta after hitting a plateau on Semaglutide or Tirzepatide.
6. Is it more powerful for fat loss? Research suggests it may be more potent for fat oxidation due to glucagon agonism.
7. Does it cause more nausea than other GLP-1s? It varies, but the triple-action can be intense if titration is too fast.
8. How should I store it? Keep reconstituted vials in the fridge; they are typically stable for up to 60 days.
9. What if I miss a dose? Administer as soon as remembered if within 4 days; otherwise, skip and wait for the next scheduled day.
10. Can I stack it with other peptides? Some stack with BPC-157 to help with GI issues, but caution is advised.
11. Will it cause muscle loss? Like all GLP-1s, high protein intake and resistance training are required to preserve lean mass.
12. Is "cold intolerance" a side effect? Yes, users frequently report feeling colder than usual.
13. How fast will I see results? While metabolic changes start early, visible weight loss usually ramps up after 4–8 weeks.

Reta / Retatrutide Trial Results

1. Phase 2 obesity trial — up to 24.2% weight loss at 48 weeks

Summary:
In adults with obesity, retatrutide produced major, dose-dependent weight loss. Lilly reported up to 24.2% average body-weight reduction at 48 weeks, equal to about 57.8 lb / 26.2 kg in the highest-dose group. Retatrutide remains investigational and is not yet approved as a treatment.

Original links:
NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Lilly: https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal

2. Strong early results — up to 17.5% weight loss at 24 weeks

Summary:
In the same Phase 2 study, Lilly reported up to 17.5% average weight loss by week 24, showing strong results halfway through the 48-week trial. The 48-week results suggested weight loss was still continuing at the end of the study period.

Original link:
Lilly: https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal

3. Phase 3 TRIUMPH-4 — weight loss plus knee osteoarthritis improvement

Summary:
Lilly reported that in its Phase 3 TRIUMPH-4 trial, retatrutide achieved an average 28.7% body-weight reduction at 68 weeks in people with obesity and knee osteoarthritis. Lilly also reported a major improvement in knee pain scores, suggesting potential benefit for obesity-related joint complications.

Original manufacturer link:
Lilly: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

4. Triple-action mechanism — GLP-1, GIP and glucagon

Summary:
Retatrutide is being researched as a triple hormone receptor agonist, targeting GLP-1, GIP and glucagon receptors. This triple mechanism is one reason researchers are watching it as a next-generation metabolic research compound.

Original link:
NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972